Allogene Therapeutics (ALLO) Equity Ratio (2018 - 2026)

Allogene Therapeutics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.7 for Q1 2026.

• In Q1 2026, Equity Ratio fell 7.17% year-over-year to 0.7; the TTM figure through Mar 2026 stood at 0.7 (down 7.17% YoY), while the FY2025 annual figure was 0.7, down 8.58% from the prior year.
• Equity Ratio came in at 0.7 for Q1 2026 at Allogene Therapeutics, roughly flat from 0.7 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2022 to a low of 0.7 in Q4 2025.
• A 5-year average of 0.78 and a median of 0.79 in 2023 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio retreated 10.79% in 2023 and decreased 0.3% in 2024, its largest moves.
• Allogene Therapeutics' Equity Ratio stood at 0.81 in 2022, then declined by 1.83% to 0.8 in 2023, then fell by 3.44% to 0.77 in 2024, then retreated by 8.58% to 0.7 in 2025, then grew by 0.13% to 0.7 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.7, 0.7, and 0.72 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison